The finding that low levels of CX3CL1 expression in tumor and plasma samples are associated with improved overall survival rates in HCC patients is consistent with the hypothesis that reducing the recruitment of immunosuppressive MDSCs may alleviate immune evasion, thereby increasing the efficacy of antitumor responses. Here, CX3CL1 is linked to hepatocellular carcinoma.